A Phase 2 interventional study of Factor XIIa antagonist monoclonal antibody and Placebo in Hereditary Angioedema, sponsored by CSL Behring. Completed at 16 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Angioedemas, Hereditary by CSL Limited — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · CSL Limited.
Among the 11 studies in Angioedemas, Hereditary by CSL Limited, this one is the only one that started in 2018, is the only one in phase 2, and was the 5th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →1 of the 11 studies in Angioedemas, Hereditary by CSL Limited is open now, in 5 countries. Recruiting first, the newest first:
CSL Behring · Sites in United States, Austria, Canada and 2 more countries
Ages 12+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 6 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2018.
This study's enrollment of 44 is close to the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 61 across the 8 interventional studies, 259 across the 2 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Angioedemas, Hereditary by CSL Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, placebo-controlled, parallel-arm, phase 2 study to investigate the clinical efficacy, pharmacokinetics, and safety of CSL312 as prophylaxis to prevent attacks in subjects with HAE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with C1-INH HAE receiving buffer only
Drug: Placebo
Subjects with C1-INH HAE receiving low dose CSL312
Biological: Factor XIIa antagonist monoclonal antibody
Subjects with C1-INH HAE receiving medium dose CSL312
Biological: Factor XIIa antagonist monoclonal antibody
Subjects with C1-INH HAE receiving high dose CSL312
Biological: Factor XIIa antagonist monoclonal antibody
Subjects with C1-INH HAE receiving medium/high dose CSL312
Biological: Factor XIIa antagonist monoclonal antibody
Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use
Also known as: CSL312
Buffer without active ingredient
The Mean Time Normalized Number of HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1
The time-normalized number of HAE attacks per month during Treatment Period 1 for a subject was calculated as the (number of HAE attacks / length of subject's evaluation period in days) \* 30.4375
Time frame: 13 weeks
The Number of Responder Subjects With C1-INH HAE During Treatment Period 1
Response is defined as a ≥ 50% relative reduction in the time-normalized number of HAE attacks (per month) during Treatment Period 1 compared to each subject's time-normalized number of HAE attacks (per month) during the Run-in Period
Time frame: 13 weeks
The Percentage of Responder Subjects With C1-INH HAE During Treatment Period 1
Response is defined as a ≥ 50% relative reduction in the time-normalized number of HAE attacks (per month) during Treatment Period 1 compared to each subject's time-normalized number of HAE attacks (per month) during the Run-in Period.
Time frame: 13 weeks
The Number of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
The Percentage of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
The Number of Mild, Moderate or Severe HAE Attacks in Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
The Percentage of Mild, Moderate or Severe HAE Attacks in Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
The Mean Time-normalized Number of Mild, Moderate or Severe HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1
The time-normalized number of HAE attacks per month during Treatment Period 1 for a subject was calculated as the (number of HAE attacks / length of subject's evaluation period in days) \* 30.4375
Time frame: 13 weeks
The Number of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
The Percentage of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
Maximum Concentration (Cmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
Area Under the Concentration-time Curve in 1 Dosing Interval (AUC0-tau) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
Time of Maximum Concentration (Tmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
Terminal Elimination Half-life (T1/2) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
Clearance (CL/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
Volume of Distribution During the Elimination Phase (Vz/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1
Time frame: 13 weeks
The Number of Subjects With C1-INH HAE With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), Injection Site Reactions (ISRs), Binding Antibodies to CSL312 During Treatment Period 1
Adverse events of special interest is defined as anaphylaxis, thromboembolic events, and bleeding events.
Time frame: 13 weeks
| Milestone | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) | CSL312 (FXII/PLG HAE) |
|---|---|---|---|---|---|---|
| Started | 8 | 9 | 8 | 7 | 6 | 6 |
| Completed | 8 | 9 | 8 | 7 | 6 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) | CSL312 (FXII/PLG HAE) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 20 | 18 | 0 | 2 |
| Completed | 0 | 0 | 20 | 16 | 0 | 2 |
| Not completed | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 |
The time-normalized number of HAE attacks per month during Treatment Period 1 for a subject was calculated as the (number of HAE attacks / length of subject's evaluation period in days) \* 30.4375
| Number of HAE attacks per month | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| The Mean Time Normalized Number of HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1 | 4.24 ± 1.801 | 0.48 ± 1.057 | 0.05 ± 0.127 | 0.35 ± 0.407 | 0.14 ± 0.222 |
Response is defined as a ≥ 50% relative reduction in the time-normalized number of HAE attacks (per month) during Treatment Period 1 compared to each subject's time-normalized number of HAE attacks (per month) during the Run-in Period
| Number of participants | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| The Number of Responder Subjects With C1-INH HAE During Treatment Period 1 | 0 | 9 | 8 | 6 | 6 |
Response is defined as a ≥ 50% relative reduction in the time-normalized number of HAE attacks (per month) during Treatment Period 1 compared to each subject's time-normalized number of HAE attacks (per month) during the Run-in Period.
| percentage of participants | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| The Percentage of Responder Subjects With C1-INH HAE During Treatment Period 1 | 0 | 100.0 | 100.0 | 85.7 | 100.0 |
| Number of participants | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| The Number of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1 | 0 | 5 | 7 | 3 | 4 |
| percentage of participants | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| The Percentage of HAE Attack-free Subjects With C1-INH HAE During Treatment Period 1 | 0 | 55.6 | 87.5 | 42.9 | 66.7 |
| Number of HAE attacks | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| Mild | 32 | 3 | 0 | 2 | 2 |
| Moderate | 43 | 9 | 1 | 4 | 0 |
| Severe | 20 | 0 | 0 | 1 | 0 |
| percentage of HAE attacks | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| Mild | 33.7 | 25.0 | 0 | 28.6 | 100.0 |
| Moderate | 45.3 | 75.0 | 100.0 | 57.1 | 0 |
| Severe | 21.1 | 0 | 0 | 14.3 | 0 |
The time-normalized number of HAE attacks per month during Treatment Period 1 for a subject was calculated as the (number of HAE attacks / length of subject's evaluation period in days) \* 30.4375
| Number of HAE attacks per month | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| Mild | 1.42 ± 1.395 | 0.12 ± 0.177 | 0.0 ± 0.000 | 0.10 ± 0.168 | 0.14 ± 0.222 |
| Moderate | 1.93 ± 1.403 | 0.36 ± 1.087 | 0.05 ± 0.127 | 0.20 ± 0.347 | 0.0 ± 0.000 |
| Severe | 0.89 ± 1.365 | 0.0 ± 0.000 | 0.0 ± 0.000 | 0.05 ± 0.136 | 0.0 ± 0.000 |
| Number of participants | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| The Number of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1 | 8 | 3 | 1 | 2 | 0 |
| percentage of participants | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| The Percentage of Subjects With at Least One (1) HAE Attack Treated With On-demand HAE Medication, in Subjects With C1-INH HAE During Treatment Period 1 | 100.0 | 33.3 | 12.5 | 28.6 | 0 |
| ug/mL | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1 | — | 10.6 ± 6.09 | 15.9 ± 5.22 | 56.4 ± 15.9 | — |
| h*μg/mL | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| Area Under the Concentration-time Curve in 1 Dosing Interval (AUC0-tau) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1 | — | 4507 ± 2424 | 7166 ± 2410 | 26514 ± 8151 | — |
| hours | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| Time of Maximum Concentration (Tmax) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1 | — | 143.38 (45.4 to 196) | 165.51 (116 to 218) | 165.63 (72.4 to 188) | — |
| hours | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| Terminal Elimination Half-life (T1/2) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1 | — | 411.7 ± 96.97 | 394.0 ± 85.64 | 443.5 ± 44.00 | — |
| L/hour | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| Clearance (CL/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1 | — | 0.0198 ± 0.0079 | 0.0303 ± 0.0084 | 0.0246 ± 0.0079 | — |
| Liters | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| Volume of Distribution During the Elimination Phase (Vz/F) of CSL312 in Subjects With C1-INH HAE During Treatment Period 1 | — | 10.6 ± 5.10 | 17.0 ± 4.78 | 17.1 ± 6.67 | — |
Adverse events of special interest is defined as anaphylaxis, thromboembolic events, and bleeding events.
| Number of participants | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) |
|---|---|---|---|---|---|
| AEs | 7 | 7 | 7 | 7 | 4 |
| SAEs | 0 | 0 | 0 | 0 | 0 |
| AESI | 1 | 0 | 0 | 0 | 0 |
| ISRs | 2 | 1 | 1 | 4 | 2 |
| Binding Antibodies to CSL312 | 1 | 0 | 0 | 0 | 0 |
Collected over Approximately 129 weeks per participant. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| CSL312 (Low) | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| CSL312 (Med) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| CSL312 (High) | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| CSL312 (Med/High) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| CSL312 (Med-Period 2) | 0/36 (0%) | 1/36 (2.8%) | 25/36 (69.4%) |
| CSL312 (Med/High-Period 2) | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| CSL312 (High-Period 2) | 0/18 (0%) | 1/18 (5.6%) | 17/18 (94.4%) |
| CSL312 (FXII/PLG HAE-Period 1) | 0/6 (0%) | 1/6 (16.7%) | 1/6 (16.7%) |
| CSL312 (FXII/PLG HAE-Period 2) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) | CSL312 (Med-Period 2) | CSL312 (Med/High-Period 2) | CSL312 (High-Period 2) | CSL312 (FXII/PLG HAE-Period 1) | CSL312 (FXII/PLG HAE-Period 2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Hereditary angioedemaCongenital, familial and genetic disorders | 0/8 | 0/9 | 0/8 | 0/7 | 0/6 | 0/36 | 0/3 | 0/18 | 1/6 | 0/2 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/8 | 0/9 | 0/8 | 0/7 | 0/6 | 0/36 | 0/3 | 1/18 | 0/6 | 0/2 |
| Diverticular perforationGastrointestinal disorders | 0/8 | 0/9 | 0/8 | 0/7 | 0/6 | 1/36 | 0/3 | 0/18 | 0/6 | 0/2 |
| Event | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) | CSL312 (Med-Period 2) | CSL312 (Med/High-Period 2) | CSL312 (High-Period 2) | CSL312 (FXII/PLG HAE-Period 1) | CSL312 (FXII/PLG HAE-Period 2) |
|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/8 | 0/9 | 0/8 | 0/7 | 0/6 | 0/36 | 0/3 | 0/18 | 0/6 | 2/2 |
| Urinary tract infectionInfections and infestations | 1/8 | 0/9 | 0/8 | 0/7 | 0/6 | 2/36 | 0/3 | 1/18 | 0/6 | 1/2 |
| PyrexiaGeneral disorders | 0/8 | 0/9 | 1/8 | 1/7 | 0/6 | 0/36 | 0/3 | 1/18 | 0/6 | 1/2 |
| DyspepsiaGastrointestinal disorders | 0/8 | 0/9 | 0/8 | 0/7 | 0/6 | 2/36 | 0/3 | 0/18 | 0/6 | 1/2 |
| HeadacheNervous system disorders | 1/8 | 0/9 | 1/8 | 2/7 | 2/6 | 6/36 | 0/3 | 4/18 | 0/6 | 1/2 |
| DizzinessNervous system disorders | 0/8 | 0/9 | 0/8 | 1/7 | 0/6 | 0/36 | 0/3 | 1/18 | 0/6 | 1/2 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/8 | 0/9 | 0/8 | 0/7 | 0/6 | 0/36 | 0/3 | 1/18 | 0/6 | 1/2 |
| Herpes zosterInfections and infestations | 0/8 | 0/9 | 0/8 | 0/7 | 0/6 | 0/36 | 0/3 | 0/18 | 0/6 | 1/2 |
| InfluenzaInfections and infestations | 0/8 | 0/9 | 0/8 | 0/7 | 0/6 | 0/36 | 0/3 | 0/18 | 0/6 | 1/2 |
| MalaiseGeneral disorders | 0/8 | 0/9 | 0/8 | 0/7 | 0/6 | 0/36 | 0/3 | 0/18 | 0/6 | 1/2 |
The Intent-to-Treat (ITT) population consisted of all subjects who provided informed consent, underwent any study screening procedure, and who were assigned to treatment in Treatment Period 1 or to treatment in Treatment Period 2, regardless of whether they received investigational product.
| Age, Categorical(Participants) | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) | CSL312 (FXII/PLG HAE) | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 9 | 8 | 6 | 6 | 6 | 43 |
| >=65 years | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) | CSL312 (FXII/PLG HAE) | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 7 | 2 | 5 | 3 | 6 | 27 |
| Male | 4 | 2 | 6 | 2 | 3 | 0 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) | CSL312 (FXII/PLG HAE) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Not Hispanic or Latino | 7 | 9 | 8 | 7 | 5 | 6 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) | CSL312 (FXII/PLG HAE) | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 2 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 7 | 9 | 8 | 5 | 4 | 6 | 39 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | CSL312 (Low) | CSL312 (Med) | CSL312 (High) | CSL312 (Med/High) | CSL312 (FXII/PLG HAE) | Total |
|---|---|---|---|---|---|---|---|
| Canada | 1 | 3 | 2 | 1 | 0 | 0 | 7 |
| United States | 4 | 2 | 0 | 2 | 2 | 1 | 11 |
| Israel | 0 | 2 | 2 | 1 | 2 | 2 | 9 |
| Germany | 3 | 2 | 4 | 3 | 2 | 3 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Oct 2021, 35 months.
Results were first posted in Nov 2022, 1 year after primary completion.
Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 35 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garadacimab